Mycophenolate mofetil (MMF) clinical trials

The OPTIMAL trial: do older adults with kidney transplants benefit from lower doses of anti-rejection tablets?

This study looks at how much anti-rejection medicine is best for older people (65+) after a kidney transplant. It compares a higher and lower dose of a common medicine called mycophenolate mofetil (MMF) to see which helps patients live longest and best, with fewest side effects.